Two studies surfaced this week that target bottlenecks in nucleic acid therapeutics: a Nature Biotechnology report mapped diverse lipid nanoparticle (LNP) shapes and linked structural differences to delivery efficiency across tissues, and an industry piece detailed the coordinated, accelerated manufacturing effort that produced a bespoke CRISPR therapy for an infant with a urea‑cycle disorder. The LNP research used complementary biophysical techniques to correlate particle architecture with functional delivery, offering a framework to tailor LNPs to specific targets. Separately, manufacturers and academic partners described the cross‑sector logistics—from mRNA CDMO supply to LNP formulation—used to compress a personalized CRISPR program into months, highlighting modular supply chains and regulatory coordination.